Jody A. Charnow

Editor

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

Prostate Cancer

Obesity Found Protective in mCRPC

Jody A. Charnow

May 18, 2020

Obese men with metastatic castration-resistant prostate cancer have superior cancer-specific and overall survival than their overweight and normal-weight counterparts, a study found.

Conservative Management Reasonable for Older Patients With ESRD

Renal Cell Carcinoma

Studies Back Active Surveillance for Small Renal Masses

Jody A. Charnow

May 18, 2020

Active surveillance for small renal masses in older patients offers long-term oncologic efficacy similar to that of partial or radical nephrectomy.

Prostate Cancer

Obesity vs Sarcopenia in Advanced Prostate Cancer

Jody A. Charnow

May 18, 2020

Greater muscle mass independently predicts longer survival in men with metastatic or castration-resistant prostate cancer, a study found.

Renal Cell Carcinoma

Expanded Use of Partial Nephrectomy Shows Promise

Jody A. Charnow

May 18, 2020

Separate studies demonstrated that partial nephrectomy could be an acceptable alternative to radical nephrectomy in selected cases of high-risk kidney cancer and large renal masses.

Bladder Cancer

Intravesical BCG Associated With Lower UTUC Recurrence Risk

Jody A. Charnow

May 18, 2020

Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a study found.

As more experience with sirolimus has been gained, it began to be used "off-label" to prevent reject

Prostate Cancer

Cytoreductive RP Beneficial in Selected Advanced Prostate Cancer Cases

Jody A. Charnow

May 18, 2020

Cytoreductive radical prostatectomy following neoadjuvant androgen-deprivation therapy (ADT) in men with hormone-naïve low-volume metastatic prostate cancer improves survival long-term vs ADT alone, a study found.

Bladder Cancer

Atezolizumab Added to Chemo Delays Metastatic Bladder Cancer Progression

Jody A. Charnow

May 15, 2020

In a phase 3 trial, atezolizumab plus platinum-based chemotherapy as first-line treatment for metastatic urothelial carcinoma improved progression-free survival vs chemotherapy alone.

General Oncology

COVID-19 Impacts Oncology Clinical Trials

Jody A. Charnow

May 15, 2020

American Society of Clinical Oncology survey shows that the COVID-19 pandemic has created challenges in how oncology clinical trials are conducted, but lessons learned from the experience could lead to more efficiently conducted trials after the pandemic has waned.

Prostate Cancer

Study: Prostate Tumors Missed by mpMRI Less Aggressive

Jody A. Charnow

May 11, 2020

Post hoc analysis of the PROMIS cohort shows that tumors undetected by mpMRI are smaller and of lower grade than those that are detected.

Low-dose Brachytherapy Provides Better Outcomes in Intermediate PCa

Prostate Cancer

Enzalutamide Added to ADT for mHSPC Preserves Health-Related Quality of Life

Jody A. Charnow

April 30, 2020

The randomized phase 3 ARCHES trial, in which men with metastatic hormone-sensitive prostate cancer received either enzalutamide or placebo in addition to androgen deprivation thrapy, found no deterioration in health-related quality of life among enzalutamide recipients.

Next post in Prostate Cancer